Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metaboli® and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
Market Cap | 1.377 Billion | Shares Outstanding | 55.581 Million | Avg 30-day Volume | 350.492 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.68 |
Price to Revenue | 266.5845 | Debt to Equity | 0.0 | EBITDA | -375.501 Million |
Price to Book Value | 1.6331 | Operating Margin | -6341.2053 | Enterprise Value | 627.792 Million |
Current Ratio | 13.733 | EPS Growth | -0.573 | Quick Ratio | 12.782 |
1 Yr BETA | 1.2328 | 52-week High/Low | 31.87 / 21.07 | Profit Margin | -6099.289 |
Operating Cash Flow Growth | 12.2482 | Free Cash Flow to Firm (FCFF) TTM | -255.6 Million | Free Cash Flow to Equity (FCFE) TTM | -261.636 Million |
Altman Z-Score | 6.6369 | ||||
Earnings Report | 2023-11-02 |
Please sign in first
none
47.9 Thousand total shares from 6 transactions
63.9 Thousand total shares from 6 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
JONES CECILIA CHIEF FINANCIAL OFFICER |
|
9,575 | 2023-09-26 | 3 |
BURNS JAMES WILLIAM CHIEF LEGAL OFFICER |
|
23,890 | 2023-08-17 | 6 |
|
2,302 | 2023-08-11 | 2 | |
|
2,302 | 2023-08-11 | 2 | |
|
13,724 | 2023-08-09 | 4 | |
GOFF BRIAN CHIEF EXECUTIVE OFFICER |
|
26,592 | 2023-08-08 | 3 |
WASHBURN THEODORE JAMES JR. PRINCIPAL ACCOUNTING OFFICER |
|
2,741 | 2023-08-07 | 7 |
GHEUENS SARAH CHIEF MEDICAL OFFICER |
|
0 | 2023-07-01 | 6 |
|
106,966 | 2023-06-28 | 4 | |
MILANOVA TSVETA CHIEF COMMERCIAL OFFICER |
|
3,831 | 2023-06-28 | 3 |
|
472,708 | 2023-06-21 | 9 | |
|
11,524 | 2023-06-21 | 2 | |
|
12,095 | 2023-06-21 | 2 | |
|
0 | 2023-06-13 | 2 | |
|
0 | 2023-06-13 | 2 | |
|
28,528 | 2022-12-31 | 1 | |
PODDAR RICHA CHIEF COMMERCIAL OFFICER |
|
18,501 | 2022-10-15 | 1 |
|
34,282 | 2022-06-21 | 0 | |
|
6,549 | 2022-05-20 | 0 | |
CAR BRUCE CHIEF SCIENTIFIC OFFICER |
|
52,500 | 2022-03-01 | 0 |
BILLER JONATHAN CHIEF FINANCIAL OFFICER |
|
57,116 | 2022-02-18 | 0 |
ALENSON CARMAN PRINCIPAL ACCOUNTING OFFICER |
|
3,555 | 2021-06-21 | 0 |
BOWDEN CHRISTOPHER CHIEF MEDICAL OFFICER |
|
16,479 | 2021-06-18 | 0 |
MILES DARRIN CHIEF COMMERCIAL OFFICER |
|
7,209 | 2021-05-14 | 0 |
HIRSCH ANDREW CHIEF FINANCIAL OFFICER |
|
24,272 | 2020-04-22 | 0 |
|
7,121,658 | 2019-11-12 | 0 | |
BILLER SCOTT CHIEF SCIENTIFIC OFFICER |
|
86,788 | 2019-06-11 | 0 |
HOERTER STEVEN L. CHIEF COMMERCIAL OFFICER |
|
10,941 | 2019-03-01 | 0 |
|
200,596 | 2017-12-06 | 0 | |
|
109,230 | 2017-03-03 | 0 | |
|
2,778 | 2016-08-10 | 0 | |
|
0 | 2016-06-21 | 0 | |
GODDARD GLENN SENIOR VICE PRESIDENT, FINANCE |
|
0 | 2016-02-16 | 0 |
HIGGONS JOHN DUNCAN CHIEF OPERATING OFFICER |
|
120,834 | 2016-01-04 | 0 |
|
0 | 2015-06-23 | 0 | |
|
184,386 | 2015-02-19 | 0 | |
ARCH VENTURE PARTNERS VII, L.P. |
|
No longer subject to file | 2015-02-19 | 0 |
|
No longer subject to file | 2015-02-19 | 0 | |
|
5,242,704 | 2014-12-16 | 0 | |
|
No longer subject to file | 2014-06-23 | 0 | |
|
5,014,059 | 2014-04-29 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-09-28 16:02:49 -0400 | 2023-09-28 | S | 2,179 | $24.79 | d | 9,575 | direct | yes | ||||||||
2023-09-28 16:02:49 -0400 | 2023-09-26 | M | 7,472 | d | 14,945 | direct | yes | |||||||||
2023-09-28 16:02:49 -0400 | 2023-09-26 | M | 7,472 | a | 11,754 | direct | yes | |||||||||
2023-08-21 16:03:44 -0400 | 2023-08-17 | S | 6,395 | $26.28 | d | 23,890 | direct | -0.4808 | -0.1109 | 0.0 | 1 | -1.6642 | 3 | |||
2023-08-15 16:06:44 -0400 | 2023-08-11 | M | 2,302 | d | 4,604 | direct | ||||||||||
2023-08-15 16:06:44 -0400 | 2023-08-11 | M | 2,302 | a | 2,302 | direct | -2.7341 | 0.7865 | -7.2285 | 5.5056 | 13 | -8.764 | 29 | |||
2023-08-15 16:04:22 -0400 | 2023-08-11 | M | 2,302 | d | 4,604 | direct | ||||||||||
2023-08-15 16:04:22 -0400 | 2023-08-11 | M | 2,302 | a | 2,302 | direct | -2.7341 | 0.7865 | -7.2285 | 5.5056 | 13 | -8.764 | 29 | |||
2023-08-11 16:04:51 -0400 | 2023-08-09 | M | 25,000 | d | 4,307 | direct | ||||||||||
2023-08-11 16:04:51 -0400 | 2023-08-09 | S | 25,000 | $25.96 | d | 11,524 | direct | 0.7991 | -2.2521 | -11.5147 | 2.3247 | 15 | -11.5147 | 31 | ||
2023-08-11 16:04:51 -0400 | 2023-08-09 | M | 25,000 | $18.09 | a | 36,524 | direct | 0.7991 | -2.2521 | -11.5147 | 2.3247 | 15 | -11.5147 | 31 | ||
2023-08-10 16:07:15 -0400 | 2023-08-08 | M | 22,691 | d | 45,382 | direct | yes | |||||||||
2023-08-10 16:07:15 -0400 | 2023-08-08 | M | 22,691 | a | 36,770 | direct | yes | 3.2633 | -1.5754 | -8.4396 | 5.6639 | 16 | -8.4396 | 31 | ||
2023-08-10 16:07:15 -0400 | 2023-08-08 | S | 10,178 | $25.48 | d | 26,592 | direct | yes | 3.2633 | -1.5754 | -8.4396 | 5.6639 | 16 | -8.4396 | 31 | |
WASHBURN THEODORE JAMES JR. - Officer PRINCIPAL ACCOUNTING OFFICER |
2023-08-09 16:04:53 -0400 | 2023-08-07 | S | 2,918 | $25.39 | d | 2,741 | direct | -0.4853 | -3.0608 | -8.436 | 5.1512 | 17 | -8.436 | 31 | |
WASHBURN THEODORE JAMES JR. - Officer PRINCIPAL ACCOUNTING OFFICER |
2023-08-02 16:02:49 -0400 | 2023-08-01 | S | 1,232 | $26.26 | d | 5,659 | direct | yes | -1.8504 | 3.2768 | 0.5783 | 8.5968 | 22 | -1.8504 | 2 |
WASHBURN THEODORE JAMES JR. - Officer PRINCIPAL ACCOUNTING OFFICER |
2023-08-02 16:02:49 -0400 | 2023-08-01 | M | 4,150 | d | 0 | direct | yes | ||||||||
WASHBURN THEODORE JAMES JR. - Officer PRINCIPAL ACCOUNTING OFFICER |
2023-08-02 16:02:49 -0400 | 2023-08-01 | M | 4,150 | a | 6,891 | direct | yes | -1.8504 | 3.2768 | 0.5783 | 8.5968 | 22 | -1.8504 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 22:15:03 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 21:45:04 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 21:15:03 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 20:45:05 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 20:15:04 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 19:45:04 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 19:15:03 UTC | 0.0 | 0.0 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 18:45:03 UTC | 0.0 | 0.0 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 18:15:03 UTC | 0.0 | 0.0 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 17:45:03 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 17:15:04 UTC | 5.0621 | 0.2579 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 16:45:04 UTC | 5.0622 | 0.2578 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 16:15:03 UTC | 5.0622 | 0.2578 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 15:45:04 UTC | 5.0632 | 0.2568 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 15:15:04 UTC | 5.0632 | 0.2568 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 14:45:04 UTC | 5.0645 | 0.2555 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 14:15:04 UTC | 5.0645 | 0.2555 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 13:45:03 UTC | 5.0648 | 0.2552 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 13:15:04 UTC | 5.0648 | 0.2552 | 2800000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-09-29 12:45:05 UTC | 5.0648 | 0.2552 | 2800000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund | AGIO | -66.0 shares, $-2310.0 | 2020-09-30 | N-PORT |
AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund | AGIO | -598.0 shares, $-19375.2 | 2019-09-30 | N-PORT |
FundVantage Trust- Gotham Master Neutral Fund | AGIO | -19.0 shares, $-665.0 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | AGIO | -119.0 shares, $-3341.52 | 2022-12-30 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | AGIO | -2700.0 shares, $-76464.0 | 2023-06-30 | N-PORT |